Physiology and Clinical Utility of HeartMate Pump Parameters
There are an estimated 300,000 patients in the United States living with heart failure (HF) who may be eligible for advanced HF therapies, specifically left ventricular assist device (LVAD) or cardiac transplantation.1–3 Owing to limited organ availability and strict patient selection, only about 3000 patients underwent cardiac transplantation in 2019.4,5 Meanwhile, LVAD technology continues to improve significantly. According to the 2019 Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) report, the 1-year survival was 82%, but recent advances in pump technology with the HeartMate 3 (HM3; Abbott, Abbott Park, IL) have improved quantity, and quality of life for these patients.